Addendum

Daratumumab (multiple myeloma) - Addendum to Commission A21-101

Report documents

Indication:

Adult patients with multiple myeloma

Result of dossier assessment:

Unchanged after addendum:

Patients who have already received 1 prior therapy with a proteasome inhibitor and lenalidomide and who were refractory to lenalidomide: added benefit not proven.

Patients who have already received ≥ 2 prior therapies containing lenalidomide and a proteasome inhibitor and who showed disease progression under or after the last therapy: added benefit not proven.

Federal Joint Committee (G-BA)

2022-02-03 A G-BA decision was published.

Project no.: A21-170
Commission: Commission awarded on 21.12.2021 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.